Clinical Efficacy and Mechanism Research of Getong Tongluo Capsule in Ischemic Stroke

The purpose of this single-center, randomized, double-blind, controlled trial is to clarify the clinical efficacy and safety of Getong Tongluo Capsule in patients with ischemic stroke. Combined with gut microbiome and metabolomics techniques, investigators will explore whether this medicine exerts neuroprotective effects via the gut-brain axis. Investigators will further verify its pharmacological mechanism through animal experiments to provide evidence for its clinical application.

NCT Number	NCT07690020
Lead Sponsor	Nanfang Hospital, Southern Medical University
Conditions	Ischemic Stroke, Acute
Enrollment	216 participants
Start Date	2026-08-01
Primary Completion	2029-07-31 (estimated)
Study Completion	2030-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-08